Attached files
file | filename |
---|---|
8-K - FORM 8-K - Xtant Medical Holdings, Inc. | v371581_8k.htm |
Bacterin Announces the
Launch of OsteoSTX, a Novel Biologic Product
BELGRADE, MT, March 13, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE) is pleased to announce the launch of OsteoSTX, a new novel allograft for orthopedic procedures. Utilizing Bacterin’s proprietary demineralization technology, OsteoSTX are flexible cortical DBM matchsticks designed for multli-level and deformity spinal applications.
“This is the first product Bacterin has launched since I joined the Company, and I have been very pleased with the process and the results,” said Dan Goldberger, Bacterin President and CEO. “We introduced this product to key opinion leaders at the NASS Evidence and Technology Spine Summit and the feedback was astounding. I am looking forward to seeing how distribution of this new product will help support our growth goals, and complement our existing product portfolio.”
OsteoSTX is the first product in Bacterin’s biologic portfolio designed specifically for addressing multi-level spine procedures
and deformity cases. Bacterin is the first company to market a product of this type for single use application. The product will
be launched this week at the 2014 AAOS Conference in New Orleans, LA, March 12th – 14th. OsteoSTX has already been implanted
in patients with strong surgeon feedback supporting the use of the product and the application.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics
products to domestic and international markets. These products are used in a variety of applications including enhancing fusion
in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following
neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops, employs, and licenses coatings for various medical device applications. For further information, please visit www.Bacterin.com.
Important Cautions Regarding Forward-looking
Statements
This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include
statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such
as "continue," "efforts," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," "projects," "forecasts," "strategy," "will,"
"goal," "target," "prospects," "potential," "optimistic," "confident,"
"likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may
be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties,
and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability
to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in
the Company’s secured lending facility; the Company’s ability to manage cash flow and achieve profitability; the Company's
ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual
property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay
and the timeliness of such payments; the Company's ability to obtain financing as and when needed; changes in consumer demands
and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the
Company’s ability to remain listed on the NYSE MKT exchange; the Company’s ability to successfully conclude government
investigations; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including
actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly
any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events, except as required by law.
Contact:
COCKRELL GROUP
877.889.1972
investorrelations@thecockrellgroup.com
cockrellgroup.com